Key facts
- It has raised $32.3M; the latest was Early Stage VC in Dec 2025.
- Notable investors include Ecole Polytechnique Federale de Lausanne, Innosuisse, Dolby Family Ventures, Eurostars, Hevolution Foundation — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Vandria
- ·The full record, as it builds
Funding rounds
No funding rounds for Vandria are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vandria
Developer of mitophagy inducers designed to rejuvenate cells to treat age-related and chronic diseases. The company's inducers are a key pathway by which portions of damaged mitochondria are eliminated and recycled using the autophagy machinery and are required to maintain proper mitochondrial function, enabling patients to avoid diseases due to old age.
- Sector
- Healthcare
- HQ
- Lausanne, Switzerland
- Founded
- 2021
- Employees
- 10
- Website
- vandria.com/
- Ownership
- Privately Held (backing)
Vandria doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vandria shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vandria in its N-PORT filings yet. We sweep new filings monthly.